Tiger Brokers

阿斯利康（AZN）第二季度总营收同比增长5% 调整后每股收益2.63美元

金吾财讯
Jul 27

金吾财讯 | 阿斯利康（AZN）今日披露二季度经营数据，核心每股收益大幅超出市场一致预期，多款肿瘤重磅药品销售实现稳步增长，当期整体营收规模小幅低于机构预期。当期核心每股收益2.63美元，较市场预期高出1.36美元；固定汇率口径下总营收153.8亿美元，同比增长5%，营收规模较市场预期低5000万美元。药品销售端，乳腺癌药物Enhertu销售额8.88亿美元，同比增长31%；肺癌药物Imfinzi营收18亿美元，同比上涨27%；公司核心畅销药Tagrisso实现收入19亿美元，同比提升6%。研发管线同步出现分化，胃癌在研疗法临床数据表现积极，用于罕见血液病的Ultomiris试验结果不及预期。阿斯利康仍预计2026年核心每股收益将实现低双位数同比增长，总营收增速为中高个位数。2025年，其营收和利润分别同比增长约8%和11%。今年以来公司股价累计下跌约8%，此前心脏病药物Wainua临床试验数据未达预期，引发市场情绪波动。公司首席执行官表态称，研发管线储备充足，未来十八个月将公布二十余项高价值临床研究结果，同时重申2026财年业绩指引，固定汇率口径总收入预计实现中高个位数增长，核心每股收益有望达成低两位数增幅。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10